AI3 Bio, Inc. — SEC Form D Filing

AI3 Bio, Inc. filed an SEC Form D on November 4, 2026 in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
November 4, 2026
Round stage
Series A
Industry
Biotechnology
Website
https://ai3.bio/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Existing autoimmune therapies manage symptoms or broadly suppress the immune system without eliminating the underlying rogue cells, causing symptoms to return when treatment ends. Additionally, newer therapies often target B cells through multi-step processes, failing to address the pathogenic T cells that drive many autoimmune diseases.

Solution

ai3Bio is developing two therapeutic platforms that directly target and eliminate disease-causing Th17 and CD161+ T cells. Its STARx platform delivers mRNA via lipid nanoparticles to prompt pathogenic T cells to self-destruct, while its T Deplete platform uses a targeted monoclonal antibody to recruit the body's immune defenses to clear those cells.

Why now

Advances in lipid nanoparticle (LNP) mRNA delivery and computational immunology now enable precise in vivo cell targeting and clearance without ex vivo cell manipulation.

Verdict

This cleared because venture capital urgently needed an in vivo delivery answer to ex vivo CAR-T manufacturing bottlenecks in autoimmune disease, not because the biology of dual Th17/CD161+ depletion was clinically de-risked. Investors implicitly bet that LNP-mediated mRNA can achieve selective in vivo cell-killing without systemic off-target toxicity or immunogenicity. The upside was capped by the company splitting focus between an avant-garde mRNA platform and a conventional monoclonal antibody asset, signaling platform hedging rather than uncompromised technical conviction.

Source: SEC EDGAR Form D filing